GlassScriptPhysician profile
Arash Bereliani
NPI 1699722165
$5,260.89
in general payments reported to CMS, 2019-2025
37 companies · $1,063 in 2025
The $1,063 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,147 · 2020: $245 · 2021: $451 · 2022: $744 · 2023: $541 · 2024: $1,071 · 2025: $1,063.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,675.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,674.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,287.57 | 2019-2025 | |
| Amgen INC. | $909.92 | 2019-2025 | Repatha, Repatha, Evenity |
| Pfizer INC. | $337.72 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $270.10 | 2019-2022 | |
| Edwards Lifesciences Corporation | $246.36 | 2022-2025 | Sapien 3 Ultra Resilia |
| E.R. Squibb & Sons, L.L.C. | $246.24 | 2019-2025 | Camzyos, Eliquis |
| Novo Nordisk INC | $231.13 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $216.30 | 2019-2025 | Jardiance |
| Biotronik INC. | $169.35 | 2019 | |
| Sanofi-Aventis U.S. LLC | $144.62 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $141.47 | 2024-2025 | |
| Alnylam Pharmaceuticals INC. | $117.00 | 2022-2024 | Amvuttra |
| Lilly USA, LLC | $95.09 | 2022-2025 | Mounjaro, Zepbound |
| Heartflow, INC. | $77.20 | 2022-2025 | Ffrct |
| Janssen Pharmaceuticals, INC | $67.46 | 2019-2023 | Xarelto |
Show all 37 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Bereliani listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.